Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$161.01 - $317.85 $45.6 Million - $90 Million
-283,170 Reduced 81.42%
64,630 $20.5 Million
Q3 2023

Nov 14, 2023

BUY
$164.66 - $218.08 $49.7 Million - $65.8 Million
301,860 Added 657.07%
347,800 $58.8 Million
Q2 2023

Aug 14, 2023

SELL
$176.32 - $240.22 $91.3 Million - $124 Million
-517,558 Reduced 91.85%
45,940 $9.96 Million
Q1 2023

May 15, 2023

BUY
$161.33 - $204.36 $78.5 Million - $99.4 Million
486,506 Added 631.89%
563,498 $102 Million
Q4 2022

Feb 14, 2023

SELL
$191.53 - $236.82 $36.6 Million - $45.3 Million
-191,108 Reduced 71.28%
76,992 $15.1 Million
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $33.2 Million - $74.4 Million
268,100 New
268,100 $60.3 Million
Q2 2022

Aug 15, 2022

SELL
$93.97 - $143.33 $18 Million - $27.5 Million
-191,800 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$98.9 - $132.37 $9.76 Million - $13.1 Million
98,703 Added 106.02%
191,800 $24.3 Million
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $10.3 Million - $14.8 Million
93,097 New
93,097 $12.2 Million
Q4 2019

Feb 14, 2020

SELL
$11.44 - $123.99 $431,711 - $4.68 Million
-37,737 Closed
0 $0
Q3 2019

Nov 15, 2019

BUY
$16.05 - $27.35 $605,678 - $1.03 Million
37,737 New
37,737 $616,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.